Health Care & Life Sciences » Pharmaceuticals | Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
60,644.00
38,984.00
88,278.00
86,556.00
17,296.00
214,985
Depreciation, Depletion & Amortization
9,782.00
9,404.00
10,238.00
9,033.00
8,349.00
12,528
Other Funds
2,513.00
1,463.00
396.00
1,861.00
-
166,484
Funds from Operations
22,532.00
1,073.00
554.00
39,430.00
130,592.00
103,481
Changes in Working Capital
86,025.00
5,212.00
20,571.00
151,535.00
43,557.00
499,407
Net Operating Cash Flow
63,493.00
6,285.00
21,125.00
112,105.00
174,149.00
602,888
Capital Expenditures
5,362.00
11,104.00
11,748.00
11,528.00
37,857.00
Purchase/Sale of Investments
250,364.00
71,744.00
48,304.00
68,127.00
320,434.00
Net Investing Cash Flow
255,726.00
82,848.00
60,052.00
56,599.00
358,291.00
Issuance/Reduction of Debt, Net
11,039.00
35,054.00
558.00
3,066.00
23,982.00
Net Financing Cash Flow
227,724.00
59,588.00
24,726.00
11,394.00
229,087.00
Net Change in Cash
35,491.00
16,975.00
14,201.00
44,112.00
44,945.00
Free Cash Flow
61,941.00
1,233.00
9,377.00
123,633.00
136,292.00
Change in Capital Stock
236,250.00
23,071.00
24,888.00
12,599.00
253,069.00

About Ionis Pharmaceuticals

View Profile
Address
2855 Gazelle Court
Carlsbad California 92010
United States
Employees -
Website http://www.ionispharm.com
Updated 07/08/2019
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.